Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01582503 · ClinicalTrials.gov registry record · Phase 2

A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)

A Phase 2 study of Asthma, sponsored by Genentech.

Completed
Registry status
Phase 2
Development phase
578
Enrollment target
20
Study locations

NCT01582503 is a Phase 2 study of Asthma that has completed, run by Genentech. The registered enrollment target is 578 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01582503, a Phase 2 study of Asthma, has completed, sponsored by Genentech.

COMPLETED
Registry status
Phase 2
Development phase
578 participants
Enrollment target
20
Study locations

Study Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients will be randomized to 4 Arms to receive subcutaneous repeating dose of either MEMP1972A 150 mg, 300 mg, or 450 mg, or placebo. Patients will continue their usual asthma medication throughout the study. Anticipated time on study treatment is 36 weeks, with a 48-week follow-up.

Conditions Studied

Asthma

Interventions

  • DRUG placebo
  • DRUG MEMP1972A

Study Locations (20)

California

  • - Bakersfield
  • - Costa Mesa
  • - Fountain Valley
  • - Long Beach
  • - Mission Viejo
  • - Rancho Cordova
  • - Redwood City
  • - Stockton
  • - Torrance
  • - Upland

Colorado

  • - Centennial
  • - Denver

Florida

  • - Tampa
  • - Winter Park

Illinois

  • - Normal
  • - River Forest

Alabama

  • - Birmingham

Connecticut

  • - New Haven

Georgia

  • - Albany

Idaho

  • - Twin Falls

Trial Details

FieldValue
Enrollment Target 578 participants
Start Date 2012-04
Est. Completion 2014-11
Phase Phase 2

Sponsor

Genentech

332 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01582503

The ClinicalTrials.gov registry entry for NCT01582503 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 578 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (63% lower). The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01582503 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT01582503 about?

NCT01582503 is a clinical study titled "A Study of MEMP1972A in Patients With Allergic Asthma Inadequately Controlled on Inhaled Steroids And A Second Controller (COSTA)". This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of 3 dosing regimens of MEMP1972A in patients with allergic asthma who remain inadequately controlled on chronic therapy with high dose inhaled corticosteroids and a second controller medication.Patients wi...

What is the current status of trial NCT01582503?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 578 participants. The study started on 2012-04. Estimated completion is 2014-11.

What conditions does trial NCT01582503 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT01582503?

The interventions under investigation include: placebo (DRUG), MEMP1972A (DRUG).

Who is sponsoring clinical trial NCT01582503?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01582503 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.